Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Allergan Freedom From Expression Suit Challenges REMS, Off-Label Powers

Executive Summary

Allergan's suit against FDA seeking a court ruling that it can provide physicians with information on unapproved uses of Botox is another milestone in the debate over off-label promotion, but it also may be the first legal indication of the power of Risk Evaluation and Mitigation Strategies to impact sales

You may also be interested in...



Free Speech Under Seal: FDA Response To Allergan Suit Challenging Off-Label Promotion Restrictions Is Kept Confidential

For the time being, FDA's response to Allergan's suit claiming First Amendment protection of off-label promotion of Botox is off limits

Free Speech Under Seal: FDA Response To Allergan Suit Challenging Off-Label Promotion Restrictions Is Kept Confidential

For the time being, FDA's response to Allergan's suit claiming First Amendment protection of off-label promotion of Botox is off limits

Pfizer's Record-Breaking $2.3 Bil. Settlement With U.S. Attorney Imposes New Restrictions on Corporate Behavior

Pfizer's $2.3 billion settlement with the U.S. Department of Justice is unprecedented in size and scope, resolving allegations of off-label marketing of four drugs and kickbacks to health care providers involving nine other drugs. Moreover, the deal includes the largest criminal fine ever imposed by the U.S. government in any matter

Related Content

Topics

UsernamePublicRestriction

Register

ID1132028

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel